27 Jan 2025 08:47 CET

Issuer

Ultimovacs ASA

Oslo, January 27, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-
stage biotechnology company developing novel immunotherapies against cancer,
invites to a webcast presentation of its fourth quarter 2024 results, on Friday,
January 31, 2025.

The presentation can be followed as a live webcast accessed through a link on
www.ultimovacs.com at 09:00 CET on Friday, January 31, 2025. The webcast
presentation will be available on the Ultimovacs website, and it will be
possible to post questions during the presentation through the webcast. Note
that the webcast presentation has been rescheduled from February 13, 2025, due
to the ongoing business combination with Zelluna Immunotherapy AS, in order to
fulfill regulatory requirements associated with this process.

The report and presentation will be available on the company website from 07:00
CET the same day.

For further information, please see www.ultimovacs.com or contact:

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA

Email: hans.eid@ultimovacs.com

Phone: +47 482 48632


Source

Ultimovacs ASA

Provider

Oslo Børs Newspoint

Company Name

ULTIMOVACS

ISIN

NO0010851603

Symbol

ULTI

Market

Oslo Børs